Simplex Trading
FDMT icon

Simplex Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Simplex Trading’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$315K Buy
+33,800
New +$294K ﹤0.01% 3780
2025
Q4 		– Sell
-3,800
Closed -$33K – 8996
2025
Q3 		$33K Buy
3,800
+1,800
+90% +$10.8K ﹤0.01% 6876
2025
Q2 		$7K Buy
2,000
+600
+43% +$2.11K ﹤0.01% 7545
2025
Q1 		$4K Sell
1,400
-12,100
-90% -$57K ﹤0.01% 7663
2024
Q4 		$75K Buy
13,500
+13,100
+3,275% +$103K ﹤0.01% 5453
2024
Q3 		$4K Sell
400
-1,300
-76% -$21.6K ﹤0.01% 7709
2024
Q2 		$35K Buy
+1,700
New +$42.6K ﹤0.01% 6406
2024
Q1 		– Sell
-500
Closed -$10K – 9139
2023
Q4 		$10K Buy
500
+100
+25% +$1.32K ﹤0.01% 7415
2023
Q3 		$5K Sell
400
-2,300
-85% -$38.5K ﹤0.01% 7641
2023
Q2 		$48K Sell
2,700
-47,600
-95% -$876K ﹤0.01% 5885
2023
Q1 		$864K Buy
50,300
+49,900
+12,475% +$970K ﹤0.01% 2723
2022
Q4 		$8K Buy
+400
New +$6.18K ﹤0.01% 7717
2022
Q3 		– Sell
-800
Closed -$5K – 10183
2022
Q2 		$5K Buy
+800
New +$7.78K ﹤0.01% 8817
2021
Q4 		– Sell
-100
Closed -$2K – 10739
2021
Q3 		$2K Hold
100
– – ﹤0.01% 9521
2021
Q2 		$2K Buy
+100
New +$3.06K ﹤0.01% 9703

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Simplex Trading's FDMT Position: Q1 2026 in Review

Simplex Trading opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 21,660 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #4285 among its holdings. This is a return to the name: Simplex Trading previously reported a position in FDMT as recently as Q3 2025.

Simplex Trading first reported a position in FDMT in Q2 2022 and has held it in 9 quarters since. The position peaked at $225K in Q4 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Simplex Trading held 21,660 shares of 4D Molecular Therapeutics worth $202K as of Q1 2026.
  • 4D Molecular Therapeutics was a new Simplex Trading position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4285 holding.
  • Simplex Trading first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • Simplex Trading's 4D Molecular Therapeutics position peaked at $225K in Q4 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.